Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Key Points

• This research aims to evaluate the efficacy and safety of oral semaglutide 25 mg for treating obesity in individuals with and without type 2 diabetes.
• Compared estimated exposure levels and efficacy of oral semaglutide 25 mg with subcutaneous semaglutide 2.4 mg.
• Utilized a model-informed drug development approach.
• Efficacy levels of oral semaglutide 25 mg were similar to those of subcutaneous semaglutide 2.4 mg.
• Support for using oral semaglutide 25 mg in treating obesity with/without type 2 diabetes.